非酒精性单纯性脂肪肝与非酒精性脂肪性肝炎患者血清脂质组学比较*

doi:10.3969/j.issn.1672-5069.2022.02.016

Abstract

Abstract: Objective The aim of this study was to analyze serum lipidomics of patients with non-alcoholic simple fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH). Methods 107 patients with NAFL and 92 patients with NASH were enrolled in our hospital between May 2015 and May 2020. The basic data were collected, and serum lipidomics were analyzed by ultra-high performance liquid chromatography-tandem mass spectrometry. Results Compared with in NAFL group, the levels of 3 kinds of free fatty acids (FFA, 12:0, 18:1 and 20:0), 2 kinds of diacylglycerols (DAG, 36:3 and 36:4), 16 kinds of triacylglycerols (TAG, 52:4, 52: 5, 54: 4, 54: 5, 54: 8, 56: 5, 56: 7, 56: 8, 56: 9, 58: 4, 58: 8, 58: 9, 58: 10, 58 : 11, 60: 6 and 60: 12), 2 kinds of phosphatidylcholines (PC, 36:5 and 38:6), 1 phosphatidylserine (PS, 33:0), 2 kinds of lysophosphatidyl ethanolamines (LPE, 36:2 and 39:1), 2 kinds of cholesterol esters (CE, 20:4 and 22:6, 4 kinds of sphingomyelins (SM, 36:3, 38:2, 40:1 and 42:1) and 3 kinds of ceramides (Cer, 40:1, 41:1 and 42:1) increased in NASH group, while 3 kinds of FFA (16: 1, 22: 4 and 22: 5), 1 TAG (54: 2), 3 types of PC (32:1, 35:4 and 38:3), 5 types of phosphatidylinositols (PI, 32:1, 34:1, 34:2, 36:4 and 40:4), 5 kinds of phosphatidalcholines (PlsCho, 34:2, 36:2, 36:4, 40:5 and 42:5) and 7 kinds of phosphatidal ethanolamines (PlsEtn, 36:6, 38:5, 38:6, 38:7, 40:7, 40:8 and 42:7) levels decreased (P<0.05). Conclusion There is a significant difference in serum lipid metabolism between patients with NAFL and patients with NASH, which might be help clarify the pathogenesis of patients with non-alcoholic simple fatty liver diseases.

Key words: Non-alcoholic steatohepatitis, Non-alcoholic simple fatty liver, Lipidomics, Ultra-high performance liquid chromatography-tandem mass spectrometry

Wang Lin, Lin Xuesong, Ding Nan. Serum lipidomics in patients with non-alcoholic simple fatty liver and non-alcoholic steatohepatitis[J]. Journal of Practical Hepatology, 2022, 25(2): 215-218.

References

[1] Fazel Y, Koenig AB, Sayiner M, et al. Epidemiology and natural history of non-alcoholic fatty liver disease. Metabolism, 2016, 65(8):1017-1025.
[2] 谢晓.无创诊断和评估非酒精性脂肪性肝炎研究进展.实用肝脏病杂志,2019, 22(2):301-304.
[3] Marengo A, Jouness RI, Bugianesi E, et al. Progression and natural history of nonalcoholic fatty liver disease in adults. Clin Liver Dis, 2016, 20(2):313-324.
[4] Castera L, Friedrich-Rust M, Loomba R. Noninvasiveassessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology, 2019, 156(5):1264-1281.
[5] Draijer LG, Froon-Torenstra D, van Weeghel M, et al. Lipidomics in nonalcoholic fatty liver disease: Exploring serum lipids as biomarkers for pediatric nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr, 2020, 71(4):433-439.
[6] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪肝专家委员会.非酒精性脂肪性肝病防治指南 (2018年版).实用肝脏病杂志,2018,21(2):177-186.
[7] Maurice J, Manousou P. Non-alcoholic fatty liver disease. Clin Med (Lond), 2018, 18(3):245-250.
[8] Bessone F, Razori MV, Roma MG. Molecular pathways of nonalcoholic fatty liver disease development and progression. Cell Mol Life Sci,2019, 76(1):99-128.
[9] Simon J, Ouro A, Ala-Ibanibo L, et al. Sphingolipids innon-alcoholic fatty liver disease and hepatocellular carcinoma: Ceramide turnover. Int J Mol Sci, 2019, 21(1):40-51.
[10] Mendez-Sanchez N, Cruz-Ramon VC, Ramirez-Perez OL, et al. New aspects of lipotoxicity in nonalcoholic steatohepatitis. Int J Mol Sci, 2018, 19(7):2034-2055.
[11] Mato JM, Alonso C, Noureddin M, et al. Biomarkers and subtypes of deranged lipid metabolism in non-alcoholic fatty liver disease. World J Gastroenterol, 2019, 25(24):3009-3020.
[12] Sa R, Zhang W, Ge J, et al. Discovering a critical transition state from nonalcoholic hepatosteatosis to nonalcoholic steatohepatitis by lipidomics and dynamical network biomarkers. J Mol Cell Biol, 2016, 8(3):195-206.
[13] Männistö V, Kaminska D, Kärjä V, et al. Total liver phosphatidylcholine content associates with non-alcoholic steatohepatitis and glycine N-methyltransferase expression. Liver Int, 2019, 39(10):1895-1905.
[14] Liu J, Wang T, He K, et al. Cardiolipin inhibitor ameliorates the non-alcoholic steatohepatitis through suppressing NLRP3 inflammasome activation. Eur Rev Med Pharmacol Sci, 2019, 23(18):8158-8167.
[15] Ma DW, Arendt BM, Hillyer LM, et al. Plasma phospholipids and fatty acid composition differ between liver biopsy-proven nonalcoholic fatty liver disease and healthy subjects. Nutr Diabet, 2016,6(7):220-227.
[16] 路晓茅,张洁,邸阜生.2型糖尿病单纯性脂肪肝与非酒精性脂肪性肝炎患者血清脂质组学的变化.中华糖尿病杂志,2020,12(1):41-47.
[17] Montefusco DJ, Allegood JC, Spiegel S, et al. Non-alcoholic fatty liver disease: Insights from sphingolipidomics. Biochem Biophys Res Commun, 2018, 504(3):608-616.
[18] Gorden DL, Myers DS, Ivanova PT, et al. Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. J Lipid Res, 2015, 56(3):722-736.
[19] Vergani L. Fattyacids and effects on in vitro and in vivo models of liver steatosis. Curr Med Chem, 2019, 26(19):3439-3456.
[20] 杨蕊旭,胡春秀,宓余强,等.非酒精性脂肪性肝病患者血清脂质组学研究.中华肝脏病杂志,2017,25(2),122-127.

Serum lipidomics in patients with non-alcoholic simple fatty liver and non-alcoholic steatohepatitis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Wang Fang, Gao Xiaoxia, Wang Qingqiang. Short-term efficacy of Huanglian Jiedu decoction and probiotics supplement in intervention of patients with non-alcoholic steatohepatitis [J]. Journal of Practical Hepatology, 2022, 25(2): 235-238.
[2]	Wen Qifu, Ma Lijun, Wang Xiaoliang. Clinical implication of serum CK18 and FGF-21 levels in patients with non-alcoholic steatohepatitis [J]. Journal of Practical Hepatology, 2021, 24(6): 835-838.
[3]	Wu limeng, Gong Xiang, Zhang Yan. Relationship between the expression of transmembrane 6 superfamily member 2 gene and cardiovascular disease in patients with non-alcoholic steatohepatitis [J]. Journal of Practical Hepatology, 2021, 24(4): 504-507.
[4]	Yuan Pingge, Chen Wenwen. Insights to new medicine development for treatment of patients with nonalcoholic steatohepatitis [J]. Journal of Practical Hepatology, 2021, 24(3): 305-307.
[5]	Wu Gang, Chen Xunjun, Zhang Wanli, et al.. Effects of dihyd rocurcumin on apoptotic pathway in palmitic acid-induced BRL-3A cell apoptosis in vitro [J]. Journal of Practical Hepatology, 2020, 23(5): 622-625.
[6]	Wang Yu, Wang Nan, Liu Yuanyuan, et al.. Effects of herbacetin onhepatic steatosis and intrahepatic oxidative stress in rats with non-alcoholic steatohepatitis [J]. Journal of Practical Hepatology, 2020, 23(5): 626-629.
[7]	Fang Jumei,Zhang Wanli,Chen Yifa ,et al.. Clinical implications of sCD163 and IL-1βmRNA in patients with nonalcoholic steatohepatitis [J]. Journal of Practical Hepatology, 2020, 23(3): 368-371.
[8]	Fu Liang, Wu Dongbing, Ji Xinzun. Application of ARFI quantification in the evaluation of liver injuries in patients with non-alcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 377-380.
[9]	Li Mengting, Li Binghang, Zhou Da, et al. Expression and activity of prolyl endopeptidase in the liver tissues of mice with non-alcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(4): 549-552.
[10]	Liu Xiaolin, Xin Fengzhi, Yang Ruixu et al. Effects of Yinzhihuang oral solution on steatosis in rat with MCD-induced non-alcoholic steatohepatitis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(3): 380-383.
[11]	Yu Hongyan, Di Fusheng. Endocrinologists should pay attention to the outcome of liver diseases in patients with diabetes and non-alcoholic fatty liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(3): 267-270.
[12]	Yang Ruixu，Hu Chunxiu，Chen Guofeng，et al.. Serum lipidomic analysis of patients with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(6): 657-662.
[13]	Xing Fengzhi, Fan Jiangao. Brief introduction of European Clinical Practice Guidelines for the management of patients with non-alcoholic fatty liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(4): 511-511.
[14]	An Xiuqin,Guo Qiaoli,Liu Jinchun,et al.. Role of CMKLR1 over-expression in adipose tissues in rat with nonalcoholic steatohepatitis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(3): 279-282.
[15]	Duan Xiaoyan, Zhang Zheng, Pan Qin, et al.. Effects of carnosic acid on the changes of serum biochemical parameters and liver histology in obese rats with non-alcoholic steatohepatitis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2012, 15(4): 295-298.